June 1 (Reuters) - The founder of 23andMe,

Anne Wojcicki, has asked a U.S. judge to reopen an auction for

the genetic testing company, saying she has the support of a

Fortune 500 company with a current market capitalization of more

than $400 billion.

Wojcicki did not name the Fortune 500 company in court

filings.

South San Francisco, California-based 23andMe filed for

bankruptcy in April, seeking to sell its business at auction

after a decline in consumer demand and a 2023 data breach that

exposed sensitive genetic and personal information of millions

of customers.

Last month, Regeneron Pharmaceuticals ( REGN ) agreed to buy

the firm for $256 million, topping a $146 million bid from

Wojcicki and TTAM Research Institute, which was founded by

Wojcicki and describes itself as a California non-profit public

benefit corporation.

In a filing dated May 31, Wojcicki claimed that 23andMe's

debtors had attempted to tilt the sales process away from TTAM

and in favor of Regeneron.

TTAM and Wojcicki said in the filing that 23andMe's

financial and legal advisers unfairly capped their maximum bid

at $250 million due to misplaced concerns about TTAM's

"financial wherewithal". The plaintiffs said the auction was

prematurely concluded before they had the opportunity to submit

a bid that would have exceeded $280 million.

The company's debtors said the auction results came after an

extensive and careful consideration by a four-member special

committee of independent directors, according to the filing.

According to another filing, 23andMe is seeking court

approval to let Wojcicki and Regeneron submit final proposals by

June 12. 23andMe is also seeking a $10 million breakup fee for

Regeneron if Wojcicki's bid is ultimately accepted.

Regeneron said it does not comment on the ongoing proceeding

and aims to close the acquisition as intended.

Lawyers for 23andMe's debtors and TTAM parties did not

immediately respond to emails seeking comment.